GeoVax receives $3.6 million grant for HIV/AIDS vaccine program
GeoVax Labs, a biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, has received a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program.
This grant was originally awarded in 2007 to GeoVax by the National Institutes of Health-National Institute of Allergy & Infectious Disease (NIH-NIAID), an agency of the U.S. Government. Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award.
GeoVax will utilize this funding to further production of its GM-CSF adjuvanted vaccine for planned human clinical trials.